AstraZeneca and Ceram Sign R&D Agreement - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

AstraZeneca and Ceram Sign R&D Agreement

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.

In a statement, Ceram CEO, Tony Kinsella, said, “This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds.”

Ceram said that controlled release is just one of the technologies being worked on by the company’s experts. Other projects involve multielement substituted hydroxyapatite for orthopaedic device coating applications. In addition, Cerma is hoping to expand its business into the US and Europe.

“Our work is focussed on commercial development of materials for industrial applications,” said Kinsella. “We have, for example, recently helped Greatbatch Medical to gain FDA (510K) approval of a coating implant submission. We have also worked with GlaxoSmithKline in the proving of its Sensodyne toothpaste.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here